INT185246

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2005
Last Reported 2011
Negated 1
Speculated 1
Reported most in Body
Documents 26
Total Number 27
Disease Relevance 8.89
Pain Relevance 3.73

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

enzyme regulator activity (Psmd1) cellular_component (Psmd1)
Anatomy Link Frequency
liver 2
embryos 1
bone marrow 1
spleen 1
sebaceous gland 1
Psmd1 (Mus musculus)
Pain Link Frequency Relevance Heat
Anterior cingulate cortex 134 100.00 Very High Very High Very High
primary somatosensory cortex 115 100.00 Very High Very High Very High
Inflammation 45 100.00 Very High Very High Very High
opioid receptor 42 99.98 Very High Very High Very High
Morphine 176 99.92 Very High Very High Very High
Locus ceruleus 8 99.20 Very High Very High Very High
Catecholamine 1 90.16 High High
Action potential 14 86.64 High High
Enkephalin 66 85.76 High High
Dopamine 2 83.68 Quite High
Disease Link Frequency Relevance Heat
Sprains And Strains 161 100.00 Very High Very High Very High
Infection 100 100.00 Very High Very High Very High
INFLAMMATION 43 100.00 Very High Very High Very High
Stomach Cancer 49 99.80 Very High Very High Very High
Hyperplasia 1 99.70 Very High Very High Very High
Targeted Disruption 295 99.36 Very High Very High Very High
Cancer 428 98.38 Very High Very High Very High
Disease 85 95.68 Very High Very High Very High
Pancreatic Cancer 59 94.32 High High
Arrhythmia Under Development 4 93.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Typical examples of the effect of morphine on CSD profiles in S1 in both WT and KO mice are shown in Figure 4A.
Gene_expression (profiles) of S1 associated with targeted disruption, primary somatosensory cortex and morphine
1) Confidence 0.50 Published 2008 Journal Mol Pain Section Body Doc Link PMC2569012 Disease Relevance 0.56 Pain Relevance 0.93
-opioid receptor responses in the ACC and S1
Gene_expression (responses) of S1 associated with primary somatosensory cortex, opioid receptor and anterior cingulate cortex
2) Confidence 0.50 Published 2008 Journal Mol Pain Section Body Doc Link PMC2569012 Disease Relevance 0.57 Pain Relevance 1.61
Stfa2l1 expression was weak or undetectable in most tissues tested, with the notable exception of the fetal liver, bone marrow, and spleen which presented high expression levels (Figure S1 and 2B).
Gene_expression (expression) of S1 in spleen
3) Confidence 0.26 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759285 Disease Relevance 0 Pain Relevance 0
These observations were unexpected given that the four deleted genes span a vast spatio-temporal spectrum of gene expression (Figures 2B and S1).
Gene_expression (expression) of S1
4) Confidence 0.26 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759285 Disease Relevance 0.12 Pain Relevance 0
Given the high degree of sequence similarity between some of the stefin members (Figure 2A), gene sequence alignments were required to design SYBR green-based qRT-PCR assays specific to Stfa1 (detecting also BC117090 and BC100530), Stfa2, Stfa2l1, and Stfa3 (Text S1 and Table S3).
Gene_expression (detecting) of S1
5) Confidence 0.26 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759285 Disease Relevance 0 Pain Relevance 0
Both BALB and A/J mice also had higher PMNs compared to B6 mice, however no additional effects of MCA on inflammatory cell types were observed within strains (Additional file 1, Table S1).
Neg (no) Gene_expression (effects) of S1 associated with inflammation and sprains and strains
6) Confidence 0.24 Published 2010 Journal Part Fibre Toxicol Section Body Doc Link PMC2861012 Disease Relevance 1.17 Pain Relevance 0.34
The xenograft tumors from mouse #5 and mouse #4 were explanted and analyzed for miR-199b-5p and HES1 expression and evaluated histopathologically (Text S1, Fig.
Spec (analyzed) Gene_expression (expression) of S1 associated with cancer
7) Confidence 0.23 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2656623 Disease Relevance 0.63 Pain Relevance 0.13
In more than 4,000 patients administered S-1 for gastric cancer, 25% have experienced grade 3 or higher toxicities, and their MST was 8.3 months.7 We herein observed an occurrence of grade 3 or higher toxicities in 9.4% of patients, a response rate of 38.4%, and a median survival rate of 343 days in the patients who received S-1 monotherapy for advanced or recurrent gastric cancer.8
Gene_expression (administered) of S-1 associated with stomach cancer
8) Confidence 0.23 Published 2010 Journal Clinical Medicine Insights. Oncology Section Body Doc Link PMC2883242 Disease Relevance 1.62 Pain Relevance 0.07
In more than 4,000 patients administered S-1 for gastric cancer, 25% have experienced grade 3 or higher toxicities, and their MST was 8.3 months.7 We herein observed an occurrence of grade 3 or higher toxicities in 9.4% of patients, a response rate of 38.4%, and a median survival rate of 343 days in the patients who received S-1 monotherapy for advanced or recurrent gastric cancer.8
Gene_expression (monotherapy) of S-1 associated with stomach cancer
9) Confidence 0.23 Published 2010 Journal Clinical Medicine Insights. Oncology Section Body Doc Link PMC2883242 Disease Relevance 1.21 Pain Relevance 0.06
Within the stefin subgroup, Csta, Cstb, and Stfa3 were expressed in a variety of tissues while Stfa1, Stfa2, and Stfa2l1 presented restricted expression patterns (Figures 2B and S1).
Gene_expression (expression) of S1
10) Confidence 0.23 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759285 Disease Relevance 0 Pain Relevance 0
Fam162a, Ccdc58, and Cst3 were highly expressed in all analyzed tissues (Figure S1 and 2B).
Gene_expression (expressed) of S1
11) Confidence 0.23 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759285 Disease Relevance 0 Pain Relevance 0
Nevertheless, Comp was still expressed in all of these tissues at levels >10-fold higher than the negative controls (Supplementary Material, Table S1).
Gene_expression (expressed) of S1
12) Confidence 0.23 Published 2010 Journal Human Molecular Genetics Section Body Doc Link PMC2792148 Disease Relevance 0.06 Pain Relevance 0
7 mice/group), and 112 genes were verified to be significantly differentially expressed (q<5%) in GF compared to SPF livers (Table S1).
Gene_expression (expressed) of S1 in livers
13) Confidence 0.22 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2734986 Disease Relevance 0 Pain Relevance 0
The information on individual characteristics is presented in Table S1.
Gene_expression (presented) of S1
14) Confidence 0.14 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504036 Disease Relevance 0.60 Pain Relevance 0.07
A synopsis summarizing clinical and laboratory features of our patients and the patients published by Hayashi et al. [13] can be found on Table S1.


Gene_expression (found) of S1
15) Confidence 0.10 Published 2010 Journal PLoS Genetics Section Body Doc Link PMC2837386 Disease Relevance 0.82 Pain Relevance 0
The distribution of podocin in the S1 and S2 fractions was similar to that of nephrin.
Gene_expression (distribution) of S1
16) Confidence 0.10 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2614475 Disease Relevance 0 Pain Relevance 0
Stfa2l1 expression was weak or undetectable in most tissues tested, with the notable exception of the fetal liver, bone marrow, and spleen which presented high expression levels (Figure S1 and 2B).
Gene_expression (expression) of S1 in bone marrow
17) Confidence 0.09 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759285 Disease Relevance 0 Pain Relevance 0
Stfa2l1 expression was weak or undetectable in most tissues tested, with the notable exception of the fetal liver, bone marrow, and spleen which presented high expression levels (Figure S1 and 2B).
Gene_expression (expression) of S1 in liver
18) Confidence 0.09 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759285 Disease Relevance 0 Pain Relevance 0
However, only 191 of these genes were differentially expressed at all four post-infection time points (Table 3 and Table S1).
Gene_expression (expressed) of S1 associated with infection
19) Confidence 0.09 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2932726 Disease Relevance 0.62 Pain Relevance 0
2.5 was selected to separate these two modes, resulting in six patients considered “high-frataxin expressers” and 21 patients designated “low-frataxin expressers” (Figure 4A and Figure S1).
Gene_expression (expressers) of S1
20) Confidence 0.08 Published 2010 Journal PLoS Genetics Section Body Doc Link PMC2799513 Disease Relevance 0.13 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox